Brain Implants Offer New Hope for Restoring Vision in Late-Stage Blindness

Brain Implants Offer New Hope for Restoring Vision in Late-Stage Blindness

2026-11-22 bio

Amsterdam, Sunday, 22 November 2026.
Bypassing damaged eyes entirely, Dutch startup Phosphoenix secured new capital to prepare human trials for an innovative brain implant that uses artificial intelligence to generate artificial sight.

Pioneering Neurotechnology in HealthTech

Operating in the specialized medical technology and healthtech sector, Phosphoenix is engineering an advanced neuroprosthetic system designed to bypass profound ocular damage and restore functional sight [1]. Across the globe, approximately 40 million individuals live with severe blindness [1]. Until now, medical science has offered no effective therapeutic interventions capable of restoring functional visual perception once the retina or the optic nerve has experienced irreparable destruction [1]. Rather than trying to rehabilitate untreatable ocular pathways, this cutting-edge biomedical innovation targets patients who had normal sight earlier in life but subsequently developed severe, progressive blindness [1].

Bypassing the Eye to Trigger Artificial Sight

Under typical biological conditions, visual signals travel from the eye to the retina before navigating neural pathways deeper into the brain [1]. Phosphoenix’s neurotechnology circumvents the eye altogether, delivering stimulation straight into cerebral processing centers [1]. The core mechanism driving this breakthrough is the Fountain Probe™, a custom-engineered implant equipped with over 1,000 micro-electrodes [1]. This array sends precise electrical impulses into the lateral geniculate nucleus (LGN), a key visual relay hub within the brain [1]. Coupled with artificial intelligence algorithms, these micro-signals generate phosphenes—perceptible points and patterns of light—that together form a functional, artificial rendering of vision [1].

Funding Milestone and the Road to Clinical Trials

To advance this neuroprosthetic pipeline, Phosphoenix secured €1.3 million in capital backed by regional development agency ROM InWest [1]. This immediate capital injection accelerates preparations for the startup’s landmark First-in-Human (FIH) clinical study scheduled for 2027, while supporting ongoing development of its proprietary neurostimulation apparatus [1]. In parallel, Phosphoenix is laying the groundwork for a broader Series A investment round targeting roughly €20 million to bankroll the comprehensive clinical development program required for eventual market approval [1].

Amsterdam’s Thriving Life Sciences Ecosystem

Based in Amsterdam, Phosphoenix emerged from deep-rooted research at the Netherlands Institute for Neuroscience (Nederlands Instituut voor Neurowetenschappen) [1]. Sara Schaafsma, investment manager at ROM InWest, underscored that this technology holds the potential to significantly enhance daily autonomy and social participation for people living with severe sight loss [1]. The startup’s trajectory mirrors the broader strength of the Amsterdam Metropolitan Area, which encompasses 25% of all Dutch Life Sciences & Health activity [2]. The regional cluster hosts over 115 medtech companies—with early-stage ventures comprising 85% of that segment—and more than 190 biotech firms, supported by institutional drivers including ROM InWest, Amsterdam UMC, and the Amsterdam Economic Board [2].

Bronnen


Neural prosthetics Medical technology